人類偏肺病毒診斷市場－全球產業規模、佔有率、趨勢、機會及預測（依技術、最終用途、地區及競爭格局分類，2021-2031年）

全球人類偏肺病毒診斷市場預計將從 2025 年的 6.1477 億美元成長到 2031 年的 10.2876 億美元，複合年成長率為 8.96%。

此細分市場包括用於鑑定呼吸道檢檢體中人類偏肺病毒（hMPV）抗原或RNA的專用試劑、檢測方法和設備。市場發展的主要促進因素是易感人群（包括嬰幼兒和老年人）急性呼吸道感染疾病的日益普遍，以及臨床上擴大採用多重檢測來區分hMPV與流感病毒和呼吸道合胞病毒（RSV）。此外，透過準確檢測病毒來改善患者照護並減少不合理使用抗生素的臨床需求也推動了市場需求。

儘管存在這些有利因素，但先進分子診斷系統實施和營運成本高昂，為市場帶來了重大障礙，阻礙了其在預算有限的醫療機構中的廣泛應用。根據美國疾病管制與預防中心（CDC）的數據，2025年3月，美國人類偏肺病毒的全國檢測陽性率為5.5%。如此高的病毒活性凸顯了持續開發經濟實惠的診斷方案以有效控制呼吸系統疾病影響的迫切需求。

市場促進因素

多症候群檢測組合的日益普及是市場成長的關鍵驅動力，它從根本上改變了臨床診療方法，使其從單一病原體檢測轉向廣泛的鑑別診斷。由於人類偏肺病毒（hMPV）相關的呼吸道症狀通常與流感或呼吸道合胞病毒（RSV）的症狀難以區分，醫療機構越來越依賴能夠同時檢測多個標靶的高通量分子檢測系統。這一轉變得益於強勁的產業表現。根據生物梅里埃公司於2025年3月發布的2024會計年度財務報告，BIOFIRE呼吸道檢測組合的銷售額成長了12%。這一趨勢的驅動力源自於症候群檢測持續的流行病學意義和重要的醫療效用。這些技術不僅能夠提供快速、可操作的診斷數據，進而加速病患分診，還能降低不必要的抗生素處方。

同時，人類偏肺病毒感染疾病的不斷增加，凸顯了對強大診斷能力的需求，尤其是在疫情過後，隨著季節性感染模式逐漸恢復正常。該病毒對兒童和老年人的負擔尤其沉重，因此需要在社區和醫院環境中頻繁進行檢測，以控制疫情爆發。 2025年4月，美國疾病管制與預防中心（CDC）在題為《有症狀人偏肺病毒感染的流行病學》的報告中指出，社區監測人群中，有症狀的人偏肺病毒感染病例發生率為每年每百人7.5例。這種活躍的病毒活動直接推動了主要產業參與者檢測量的增加。例如，丹納赫公司在2025年報告稱，其子公司Cefeed的呼吸系統診斷部門僅在2024年第四季就實現了約5.5億美元的收入，這凸顯了感染率所支撐的巨大市場規模。

市場挑戰

全球人類偏肺病毒（hMPV）診斷市場擴張的主要障礙在於先進分子偵測系統相關的高昂資本和營運成本。儘管這些診斷平台具備準確識別hMPV所需的靈敏度，但其高昂的進入門檻對資金預算有限的醫療機構構成了重大阻礙。檢查室經常面臨兩難：既要權衡廣泛呼吸道病原體檢測的臨床獲益，又要承擔設備維護、專用試劑和人員培訓等持續高昂成本。這種經濟負擔阻礙了分子檢測在社區醫院和門診診所的廣泛應用，實際上將市場限制在資源雄厚的學術機構。

預算限制的影響因醫療服務成本的不斷上漲而加劇，導致可用於實驗室改進的自由支配資金減少。隨著醫療機構營運成本的不斷攀升，採購部門擴大推遲對昂貴診斷技術的投資，轉而選擇更經濟的傳統檢測方案。根據美國醫院協會預測，到2024年，醫院總成本將成長5.1%，這一增幅遠高於通膨率。以金額為準的經濟壓力迫使管理者實施嚴格的成本控制策略，並直接限制了臨床實驗室部署高通量分子檢測系統的能力，而這些系統對於有效檢測人類乳突病毒（hMPV）至關重要。

市場趨勢

照護現場（POC）的廣泛應用正在顯著改變市場格局，將檢測流程從集中式檢查室轉移到更貼近患者的場所。這種去中心化滿足了小兒科和急診護理環境中對快速檢測結果的迫切需求，因為在這些環境中，立即檢測出人類偏肺病毒（hMPV）對治療方案和隔離通訊協定至關重要。為此，製造商正在推出緊湊、直覺的平台，這些平台能夠在標準醫院環境之外提供檢查室層級的精準度，從而確保社區的診斷服務。這項基礎診斷技術的持續需求也反映在近期的財務表現上。根據雅培公司於2024年10月發布的“2024會計年度第三季度財務業績”，其全球診斷銷售額（不包括新冠病毒檢測）實現了3.3%的有機成長，表明公司核心診斷業務的穩健擴張。

同時，將人類偏肺病毒（hMPV）納入呼吸道疾病監測計畫正逐漸成為追蹤季節性病毒波動的重要趨勢。公共衛生機構日益重視將hMPV與流感病毒和呼吸道合胞病毒（RSV）一起納入國家監測體系，以便更準確地預測疫情高峰並有效分配醫療資源。這種日益成長的關注源於呼吸道病毒大規模爆發後出現的不規則傳播模式，因此需要全面的數據來指導疫苗監測和防治措施。近期流行病學統計數據也凸顯了這種監測的必要性。根據Truveta公司2024年12月發布的《監測報告：呼吸道病毒－2024年11月資料》，2024年10月下旬至11月下旬，與人類偏肺病毒相關的住院人數激增172.7%，凸顯了持續進行多病原體追蹤機制的重要性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球人類偏肺病毒診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依技術分類（基於PCR的診斷、次世代定序（NGS）、螢光、橫向流動化驗、微陣列技術、其他）
  • 依用途（醫院/診所、診斷/檢測機構、學術/研究機構、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美人類偏肺病毒診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲人類偏肺病毒診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區人類偏肺病毒診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲人類偏肺病毒診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲人類偏肺病毒診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球人類偏肺病毒診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• QuidelOrtho Corporation
• ARUP Laboratories, Inc.
• DiaSorin SpA
• R-Biopharm AG
• Seegene Inc.
• ZeptoMetrix LLC
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Human Metapneumovirus Diagnostics Market is projected to expand from USD 614.77 Million in 2025 to USD 1028.76 Million by 2031, registering a CAGR of 8.96 percent. This sector comprises the specialized reagents, assays, and instrumentation required to identify viral antigens or RNA of hMPV in respiratory samples. Market progression is primarily fueled by the rising prevalence of acute respiratory infections among susceptible populations, including infants and the elderly, as well as a growing clinical inclination toward multiplex testing panels that distinguish hMPV from Influenza and RSV. Additionally, the demand is bolstered by the clinical imperative to refine patient care and curtail inappropriate antibiotic administration through precise viral detection.

Despite these favorable drivers, the market encounters significant obstacles related to the substantial acquisition and operating expenses of sophisticated molecular diagnostic systems, which hinders their broad implementation in healthcare settings with limited budgets. Data from the Centers for Disease Control and Prevention indicated a national test positivity rate for human metapneumovirus of 5.5 percent in the United States during March 2025. This elevated level of viral activity highlights the enduring necessity for affordable diagnostic options to effectively manage the impact of respiratory diseases.

Market Driver

The increasing utilization of Multiplex Syndromic Testing Panels serves as a key catalyst for market growth, fundamentally transforming clinical approaches from single-pathogen testing to broad differential diagnosis. Because respiratory symptoms associated with hMPV are often indistinguishable from those of Influenza and RSV, medical providers are increasingly depending on high-throughput molecular systems capable of detecting multiple targets simultaneously. This shift is corroborated by robust industry performance; according to bioMerieux's '2024 Financial Results' released in March 2025, sales for BIOFIRE respiratory panels rose by 12 percent, a trend driven by the enduring epidemiology and significant medical utility of syndromic testing. These technologies not only accelerate patient triage but also reduce the likelihood of unneeded antibiotic prescriptions by providing quick and actionable diagnostic data.

Concurrently, the escalating incidence of Human Metapneumovirus infections is heightening the need for a strong diagnostic framework, especially as seasonal transmission patterns normalize following the pandemic. The virus places a substantial strain on pediatric and elderly groups, requiring frequent testing to control outbreaks in both community and hospital environments. In April 2025, the Centers for Disease Control and Prevention reported in the 'Epidemiology of Symptomatic Human Metapneumovirus Infection' that the incidence rate of symptomatic hMPV infection stood at 7.5 cases per 100 individuals annually within community surveillance groups. This intense viral activity directly supports high testing volumes for leading industry participants; for instance, Danaher Corporation reported in 2025 that its subsidiary Cepheid's respiratory diagnostics division achieved approximately 550 million dollars in revenue during the fourth quarter of 2024 alone, highlighting the significant market scale sustained by infection rates.

Market Challenge

A major obstacle impeding the expansion of the Global Human Metapneumovirus Diagnostics Market is the significant capital and operational expense linked to sophisticated molecular testing systems. Although these diagnostic platforms offer the sensitivity required for accurate hMPV identification, their steep acquisition prices present a formidable entry barrier for healthcare institutions operating with restricted capital budgets. Laboratories frequently face the difficult task of balancing the clinical advantages of extensive respiratory panels against the substantial recurring costs needed for equipment maintenance, specialized reagents, and staff training. This financial strain precludes the widespread implementation of molecular assays in community hospitals and outpatient clinics, effectively confining the market primarily to well-resourced academic centers.

The effect of these budgetary limitations is exacerbated by the increasing costs of healthcare delivery, which diminish the discretionary funds available for laboratory improvements. As healthcare organizations confront escalating operational overheads, procurement departments often postpone investments in high-end diagnostic technologies in favor of more economical, conventional testing options. According to the American Hospital Association, total hospital expenses rose by 5.1 percent in 2024, a rate significantly exceeding general inflation. This growing economic pressure compels administrators to enforce rigorous cost-control strategies, directly obstructing clinical laboratories' capacity to acquire the high-throughput molecular systems essential for effective hMPV detection.

Market Trends

The proliferation of Point-of-Care (POC) Molecular Diagnostics is significantly reshaping the market by moving testing procedures from centralized laboratories to near-patient environments. This decentralization fulfills the urgent requirement for rapid results in pediatric and urgent care settings, where the immediate detection of hMPV can decisively impact treatment plans and isolation protocols. In response, manufacturers are introducing compact, intuitive platforms that provide laboratory-grade accuracy outside of standard hospital settings, ensuring diagnostic availability in community locations. This ongoing demand for fundamental diagnostic technologies is reflected in recent financial outcomes; according to Abbott's 'Third-Quarter 2024 Results' published in October 2024, global diagnostic sales, excluding COVID-19 testing, grew by 3.3 percent on an organic basis, indicating robust expansion in the core diagnostic business.

Simultaneously, the incorporation of hMPV into Pan-Respiratory Surveillance Programs is developing as a crucial trend for tracking seasonal viral fluctuations. Public health organizations are increasingly prioritizing the addition of hMPV alongside Influenza and RSV in national monitoring efforts to more accurately forecast outbreak surges and deploy hospital resources effectively. This heightened focus is motivated by the erratic circulation patterns seen following widespread respiratory virus disruptions, necessitating comprehensive data to guide vaccination research and containment measures. The necessity of this surveillance is emphasized by recent epidemiological statistics; according to Truveta's December 2024 'Monitoring Report: Respiratory Viruses - November 2024 Data,' hospitalizations associated with human metapneumovirus surged by 172.7 percent between late October and late November 2024, highlighting the critical need for continuous, multi-pathogen tracking mechanisms.

Key Market Players

• QuidelOrtho Corporation
• ARUP Laboratories, Inc.
• DiaSorin S.p.A.
• R-Biopharm AG
• Seegene Inc.
• ZeptoMetrix LLC
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc

Report Scope

In this report, the Global Human Metapneumovirus Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Metapneumovirus Diagnostics Market, By Technology

• PCR-based Diagnostics
• Next-generation Sequencing (NGS)
• Immunofluorescence Assays
• Lateral Flow Assays
• Microarray Technology
• Others

Human Metapneumovirus Diagnostics Market, By End Use

• Hospitals & Clinics
• Diagnostic & Reference Laboratories
• Academic & Research Institutions
• Others

Human Metapneumovirus Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Metapneumovirus Diagnostics Market.

Available Customizations:

Global Human Metapneumovirus Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Metapneumovirus Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (PCR-based Diagnostics, Next-generation Sequencing (NGS), Immunofluorescence Assays, Lateral Flow Assays, Microarray Technology, Others)
  • 5.2.2. By End Use (Hospitals & Clinics, Diagnostic & Reference Laboratories, Academic & Research Institutions, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Human Metapneumovirus Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Metapneumovirus Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By End Use
  • 6.3.2. Canada Human Metapneumovirus Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By End Use
  • 6.3.3. Mexico Human Metapneumovirus Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By End Use

7. Europe Human Metapneumovirus Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By End Use
  • 7.3.2. France Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By End Use

8. Asia Pacific Human Metapneumovirus Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By End Use
  • 8.3.3. Japan Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By End Use
  • 8.3.4. South Korea Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By End Use

9. Middle East & Africa Human Metapneumovirus Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Human Metapneumovirus Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By End Use
  • 9.3.2. UAE Human Metapneumovirus Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By End Use
  • 9.3.3. South Africa Human Metapneumovirus Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By End Use

10. South America Human Metapneumovirus Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Human Metapneumovirus Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By End Use
  • 10.3.2. Colombia Human Metapneumovirus Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By End Use
  • 10.3.3. Argentina Human Metapneumovirus Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Human Metapneumovirus Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QuidelOrtho Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ARUP Laboratories, Inc.
• 15.3. DiaSorin S.p.A.
• 15.4. R-Biopharm AG
• 15.5. Seegene Inc.
• 15.6. ZeptoMetrix LLC
• 15.7. Abbott Laboratories Inc.
• 15.8. Thermo Fisher Scientific Inc.
• 15.9. F. Hoffmann-La Roche Ltd.
• 15.10. Bio-Rad Laboratories, Inc

16. Strategic Recommendations

17. About Us & Disclaimer